文献速递新发突发、热带与寄生虫病艾滋病与性传播感染

MVA-BN疫苗诱导抗体两年持久性及高风险人群猴痘突破感染风险

Two-year durability of MVA-BN vaccine-induced antibodies and the risk of Mpox breakthrough infections among high-risk populations: a prospective, longitudinal study.
PubMed 文献 · Clin Microbiol Infect · 2026-08-03

该前瞻性纵向研究纳入452名完成两剂MVA-BN疫苗的男男性行为者及27名猴痘确诊者,随访24个月。接种后2年抗A29/抗H3 IgG血清阳性率在有HIV者中为19.5%/12.6%,无HIV者为18.4%/9.2%,有天花疫苗接种史者为48.9%/51.1%;自然感染者分别为18.2%和72.7%。随访发现6例突破感染,中位828天,症状较轻但仍有重症。

要点

  • 两剂MVA-BN接种后2年体液免疫显著下降,无天花疫苗接种史者尤甚。
  • 有天花疫苗接种史或自然猴痘感染与较低血清转阴风险独立相关。
  • 突破感染可发生于接种2年后,虽病变较少但仍可重症。

核心结论

  • 两剂MVA-BN疫苗后体液免疫随时间减弱,无天花疫苗接种史者下降更明显。
  • 自然猴痘感染诱导的猴痘病毒特异性IgG应答更持久。
  • 突破感染可能在接种2年后发生,但疾病通常较轻,仍需持续监测和考虑加强策略。

研究设计与样本

  • 前瞻性纵向研究,纳入≥18岁完成两剂MVA-BN接种的男男性行为者425人及PCR确诊猴痘者27人。
  • 连续检测接种或诊断后24个月内抗A29和抗H3 IgG。
  • 主要结局为2年时两种抗体血清阳性比例,次要结局包括抗体动力学、突破感染和无症状感染血清学证据。

主要发现

  • 接种后2年,有HIV者抗A29/抗H3 IgG血清阳性率为19.5%/12.6%,无HIV者为18.4%/9.2%,有天花疫苗接种史者为48.9%/51.1%。
  • 自然感染者2年抗A29和抗H3 IgG血清阳性率分别为18.2%和72.7%。
  • 随访发现6例突破感染,中位接种后828天,通常生殖器外病变较少但仍有重症。
  • 20人抗A29和抗H3 IgG均≥4倍升高且无症状,提示无症状感染。

关键数值与推荐

  • 2年血清阳性率:有HIV者抗A29 19.5%、抗H3 12.6%;无HIV者18.4%/9.2%;有天花疫苗接种史者48.9%/51.1%。
  • 自然感染者2年抗A29/抗H3 IgG血清阳性率为18.2%/72.7%。
  • 突破感染中位时间828天。
  • 20人抗体≥4倍升高提示无症状感染。

临床怎么用

  • 对高风险人群应持续监测猴痘突破感染,即使接种已超过2年。
  • 无天花疫苗接种史者抗体下降更快,可考虑加强接种策略。
  • 突破感染可能症状不典型,需警惕生殖器外病变较少的情况。

局限性

  • 研究未明确报告免疫保护 correlates,需进一步研究。
  • 样本量有限,尤其自然感染组仅27人。
  • 观察性设计可能存在混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Since the 2022 global Mpox outbreak, vaccination programmes using the MVA-BN vaccines have been widely implemented. However, the durability of vaccine-induced immunity remains incompletely understood. METHODS: Men who have sex with men aged ≥18 years who completed two-dose MVA-BN vaccination were enrolled in a prospective vaccination cohort. Participants with PCR-confirmed Mpox were enrolled as a comparison cohort. Anti-A29 and anti-H3 IgG were determined serially up for 24 months after vaccination or Mpox diagnosis. The primary outcome was the proportion of participants remaining seropositive for the two antibodies at 2 years. Secondary outcomes included antibody kinetics, breakthrough infection, and serological evidence suggesting asymptomatic infection. RESULTS: A total of 452 participants were enrolled, including 425 in the vaccination cohort and 27 in the Mpox cohort. At 2 years after vaccination, anti-A29/anti-H3 IgG seropositivity was 19.5%/12.6% among people with HIV, 18.4%/9.2% among people without HIV, and 48.9%/51.1% among participants with prior smallpox vaccination. In addition, among participants with natural Mpox infection, 2-year seropositivity for anti-A29 and anti-H3 IgG was 18.2% and 72.7%, respectively. Prior smallpox vaccination and natural Mpox infection were independently associated with a lower risk of seroreversion. During follow-up, six breakthrough Mpox infections were identified at a median of 828 days after vaccination. Breakthrough cases generally presented with fewer extragenital lesions than unvaccinated cases, although severe disease still occurred. Twenty participants demonstrated ≥4-fold increases in both anti-A29 and anti-H3 IgG without compatible symptoms, suggesting asymptomatic infection. CONCLUSIONS: Humoral immunity after two-dose MVA-BN vaccination wanes over time, particularly among individuals without prior smallpox vaccination, whereas natural Mpox infection is associated with more durable Mpox virus-specific IgG responses. Breakthrough infections may occur more than 2 years after vaccination despite generally attenuated disease. These findings highlight the need for continued surveillance, consideration of booster vaccination strategies, and further investigation into immune correlates of protection against Mpox.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Liu WD, Chan UM, Chao TL, et al. Two-year durability of MVA-BN vaccine-induced antibodies and the risk of Mpox breakthrough infections among high-risk populations: a prospective, longitudinal study. Clin Microbiol Infect. 2026. PMID: 42546923. doi:10.1016/j.cmi.2026.07.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。